Trinity Biotech Files Routine 6-K Report
Ticker: TRIB · Form: 6-K · Filed: Jan 29, 2025 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Jan 29, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $1.8 million, $4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, 6-K, foreign-private-issuer
TL;DR
Trinity Biotech filed a standard 6-K, no major news.
AI Summary
Trinity Biotech plc filed a Form 6-K on January 29, 2025, to report information for the month of January 2025. The company, based in Ireland, is a foreign private issuer and is submitting its report under the Securities Exchange Act of 1934. This filing does not appear to contain specific financial figures or material events beyond its routine reporting status.
Why It Matters
This filing indicates Trinity Biotech is fulfilling its ongoing reporting obligations as a foreign private issuer, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information or financial data.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- 0001178913-25-000251 (accession_number) — Filing identifier
- 20250129 (date) — Filing date
FAQ
What type of company is Trinity Biotech plc?
Trinity Biotech plc is a foreign private issuer operating in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry.
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of January 2025.
Where is Trinity Biotech plc's principal executive office located?
Trinity Biotech plc's principal executive office is located at IDA Business Park, Bray, Co. Wicklow, Ireland.
Does Trinity Biotech plc file annual reports under Form 20-F?
Yes, the filing indicates that Trinity Biotech plc files annual reports under cover of Form 20-F.
What is the Central Index Key (CIK) for Trinity Biotech plc?
The Central Index Key (CIK) for Trinity Biotech plc is 0000888721.
Filing Stats: 1,267 words · 5 min read · ~4 pages · Grade level 15.4 · Accepted 2025-01-29 17:15:02
Key Financial Figures
- $1.8 million — d received loans totaling approximately $1.8 million under the Paycheck Protection Program (
- $4 million — the subsidiaries received approximately $4 million of loans which were subsequently forgiv
Filing Documents
- zk2532620.htm (6-K) — 18KB
- 0001178913-25-000251.txt ( ) — 20KB
Forward-Looking Statements
Forward-Looking Statements This filing includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech's cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company's distributors, losses or system failures with respect to Trinity Biotech's facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech's products and services, the continuing development of its products, required government approvals, continuing international government financial support for healthcare programs, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: January 29 , 2025